Definium Therapeutics, Inc.
Definium Therapeutics, Inc. (DFTX) Stock Overview
Explore Definium Therapeutics, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
1.8B
P/E Ratio
-8.65
EPS (TTM)
N/A
ROE
-0.84%
DFTX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Definium Therapeutics, Inc. (DFTX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 55.60, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $66.46.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -8.65 and a market capitalization of 1.8B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.